Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Nigella Sativa  COVID-19 treatment studies for Nigella Sativa  C19 studies: Nigella Sativa  Nigella Sativa   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Recovery, day 10, dyspnea 62% Improvement Relative Risk Recovery, day 10, smell -280% Recovery, day 10, taste -166% Recovery, day 10, fatigue -4% Recovery, day 10, heada.. -42% Recovery, day 5, dyspnea 42% Recovery, day 5, fever 73% Recovery, day 5, smell -93% Recovery, day 5, taste -61% Recovery, day 5, fatigue 22% Recovery, day 5, headache -3% c19early.org/ns Bin Abdulrahman et al. Nigella Sativa for COVID-19 RCT EARLY Favors nigella sativa Favors control
The Effect of Short Treatment with Nigella Sativa on Symptoms, the Cluster of Differentiation (CD) Profile, and Inflammatory Markers in Mild COVID-19 Patients: A Randomized, Double-Blind Controlled Trial
Bin Abdulrahman et al., International Journal of Environmental Research and Public Health, doi:10.3390/ijerph191811798
19 Sep 2022    Source   PDF   Share   Tweet
RCT 262 mild cases in Saudi Arabia, showing no significant difference in outcomes. The only symptomatic outcomes provided are for individual symptoms, with large differences in the baseline frequencies. 75 patients were lost to followup with the primary reason being early recovery. A higher percentage of patients were lost to followup in the treatment groups.
risk of no recovery, 62.0% lower, RR 0.38, p = 0.37, treatment 4 of 179 (2.2%), control 1 of 17 (5.9%), NNT 27, all treatment groups combined, day 10, dyspnea.
risk of no recovery, 279.9% higher, RR 3.80, p = 0.21, treatment 40 of 179 (22.3%), control 1 of 17 (5.9%), all treatment groups combined, day 10, smell.
risk of no recovery, 165.9% higher, RR 2.66, p = 0.48, treatment 28 of 179 (15.6%), control 1 of 17 (5.9%), all treatment groups combined, day 10, taste.
risk of no recovery, 4.5% higher, RR 1.04, p = 1.00, treatment 11 of 179 (6.1%), control 1 of 17 (5.9%), all treatment groups combined, day 10, fatigue.
risk of no recovery, 42.5% higher, RR 1.42, p = 1.00, treatment 15 of 179 (8.4%), control 1 of 17 (5.9%), all treatment groups combined, day 10, headache.
risk of no recovery, 41.7% lower, RR 0.58, p = 0.35, treatment 13 of 212 (6.1%), control 2 of 19 (10.5%), NNT 23, all treatment groups combined, day 5, dyspnea.
risk of no recovery, 73.1% lower, RR 0.27, p = 0.06, treatment 9 of 212 (4.2%), control 3 of 19 (15.8%), NNT 8.7, all treatment groups combined, day 5, fever.
risk of no recovery, 92.7% higher, RR 1.93, p = 0.14, treatment 86 of 212 (40.6%), control 4 of 19 (21.1%), all treatment groups combined, day 5, smell.
risk of no recovery, 61.3% higher, RR 1.61, p = 0.31, treatment 72 of 212 (34.0%), control 4 of 19 (21.1%), all treatment groups combined, day 5, taste.
risk of no recovery, 22.3% lower, RR 0.78, p = 0.58, treatment 52 of 212 (24.5%), control 6 of 19 (31.6%), NNT 14, all treatment groups combined, day 5, fatigue.
risk of no recovery, 3.1% higher, RR 1.03, p = 1.00, treatment 46 of 212 (21.7%), control 4 of 19 (21.1%), all treatment groups combined, day 5, headache.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in meta analysis: only individual symptom data provided, differences in baseline frequencies, significant loss to followup due to recovery with greater frequency in treatment groups.
Bin Abdulrahman et al., 19 Sep 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Saudi Arabia, peer-reviewed, mean age 35.2, 14 authors.
Contact: kab@imamu.edu.sa (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperNigella SativaAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit